Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK10 | P53779 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 6/20 | 0.54 |
| ▸ | GAA | P10253 | 6/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.54 |
| ▸ | MEN1 | O00255 | 4/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | PLAU | P00749 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | APP | P05067 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | SNCA | P37840 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3265738 | 0.84 | MEN1 (0.58) | MAPK10MAPTKDM4EMEN1KMT2A | |
| SCHEMBL4943709 | 0.79 | MEN1 (0.73) | MAPK10MAPTGAAKDM4EMEN1 | |
| SCHEMBL2677107 | 0.78 | MAPT (0.71) | MAPK10MAPTGAAKDM4EMEN1 | |
| SCHEMBL16036495 | 0.78 | ULK1 (0.46) | MAPK10MAPTGAAALDH1A1LMNA | |
| SCHEMBL16089617 | 0.78 | PLAU (0.44) | MAPTGAAKDM4EMEN1KMT2A | |
| SCHEMBL4765871 | 0.77 | IKBKB (0.55) | MAPK10HDAC1EGFR | |
| SCHEMBL29581676 | 0.76 | MAPT (0.50) | MAPK10MAPTGAAKDM4EMEN1 | |
| SCHEMBL28104565 | 0.76 | MAPT (0.54) | MAPK10MAPTGAAKDM4EMEN1 | |
| SCHEMBL11901257 | 0.75 | PLAU (0.41) | MAPK10ALDH1A1PLAUHDAC1HDAC3 | |
| SCHEMBL3950995 | 0.74 | HTT (0.56) | MAPK10GAAKDM4EKMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104109127-B | Kinase inhibitor and the method for treating related disease | 北京大学深圳研究生院 | 2019-11-05 | — | — | CN | disclosed |
| CN-104109127-B | Kinase inhibitor and the method for treating related disease | 北京大学深圳研究生院 | 2019-11-05 | — | — | CN | disclosed |
| CN-109305944-A | The inhibitor of bruton's tyrosine kinase | 深圳睿熙生物科技有限公司 | 2019-02-05 | — | — | CN | disclosed |
| CN-103073508-B | The method of inhibitors of kinases and treatment relevant disease | PEKING UNIVERSITY SHENZHEN GRADUATE SCHOOL (CN) | 2016-06-01 | — | — | CN | disclosed |
| CN-103073508-B | The method of inhibitors of kinases and treatment relevant disease | PEKING UNIVERSITY SHENZHEN GRADUATE SCHOOL (CN) | 2016-06-01 | — | — | CN | disclosed |
| US-20130172570-A1 | METHOD OF MAKING BENZAZOLES | US GOVERNMENT AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) | 2013-07-04 | — | — | US | disclosed |
| US-20130172570-A1 | METHOD OF MAKING BENZAZOLES | US GOVERNMENT AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) | 2013-07-04 | — | — | US | disclosed |
| EP-0756602-B1 | CCK OR GASTRIN MODULATING 5-HETEROCYCLIC-1,5-BENZODIAZEPINES | GLAXO WELLCOME INC (US) | 1999-06-30 | — | — | EP | disclosed |
| US-5739129-A | AGONIST ACTIVITY | GLAXO WELLCOME INC. (US) | 1998-04-14 | — | — | US | disclosed |
| EP-0756602-A1 | CCK OR GASTRIN MODULATING 5-HETEROCYCLIC-1,5-BENZODIAZEPINES | GLAXO WELLCOME INC. (US) | 1997-02-05 | — | — | EP | disclosed |
| WO-1995028419-A1 | CCK OR GASTRIN MODULATING 5-HETEROCYCLIC-1,5-BENZODIAZEPINES | GLAXO WELLCOME INC. (US) | 1995-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172570-A1 | METHOD OF MAKING BENZAZOLES | NBAS, CBR3, CBR1 | MAPK10 4804/4885MAPT 4648/4885GAA 2817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.